Intranigral injection of lipopolysaccharide (LPS), a potent inductor of inflammation, induces degeneration of dopaminergic neurons, along with an inflammatory process that features activation of microglial cells and loss of astrocytes. To test the involvement of dopamine (DA) in this degeneration induced by LPS, we treated albino Wistar rats with different concentrations of α-methyl-p-tyrosine (α-MPT), an inhibitor of tyrosine hydroxylase (TH) activity. Results showed that α-MPT prevented LPS-induced loss of TH immunostaining and expression of mRNA for TH and DA transporter; it also prevented substantial activation of microglial cells. Loss of the astroglial population, a marker of damage in our model, was also prevented. This protective effect resulted from inhibition of TH and the consequent decrease in DA concentration, because treatment with L-DOPA/benserazide, which bypasses TH inhibition induced by α-MPT, reversed the protective effect produced by this drug. These results point out the important contribution of DA to the vulnerability and degeneration of dopaminergic neurons of the substantia nigra. Knowledge about the involvement of DA in this process may lead to the possibility of new protection strategies against this important degenerative process.
dopaminergic neurons in PD. McGeer et al. (5, 6) showed the presence of CD + T-cytotoxic suppressor lymphocytes and HLA-DR antigen-positive-activated microglial cells in affected central nervous system tissue of patients with PD. Different kinds of inflammatory features have also been described in parkinsonian brains (7) . These data allow the postulation that inflammatory events may be substantially involved in the pathogenesis of PD (8). We previously demonstrated in vivo that DA neurons are sensitive to the inflammogen lipopolysaccharide (LPS) (9). Intranigral injection of LPS produced activation of microglial cells along with progressive degeneration of the dopaminergic system, as indicated by a significant decrease in DA levels in both SN and striatum (9). At the same time, LPS did not induce damage of GABAergic neurons in vivo, as indicated by the unaltered transcription of glutamic acid decarboxylase (GAD) mRNA after LPS injection in the SN and striatum. Serotonergic cells were also unaffected, because immunostaining did not change after LPS injection into the dorsal raphe (10). Similarly, hippocampal and cortical neurons remained insensitive to LPS treatment (11). Many studies have investigated the reason for the special vulnerability of the SN dopaminergic neurons. The sensitivity of the structure could be related to the fact that it contains the highest density of microglial cells in the brain (12) and consequently a high concentration of the inflammation-related factors produced by these cells, such as tumor necrosis factor-α and nitric oxide. This proposal is supported by the fact that many anti-inflammatory compounds protect dopaminergic neurons. However, this finding cannot justify the special sensitivity of dopaminergic neurons within the SN.
The high vulnerability of dopaminergic neurons to oxidative stress has been suggested to be a consequence of the reduced antioxidant capacity and the high content of iron and DA in the SN (13) . In addition, there is general agreement on the toxic capability of DA, which generates redox metabolites including semiquinone, quinone, zwitterionic 5,6-hydroxyindoles, and possibly oxygen free radicals. This DA neurotoxicity, in theory, also accelerates autoxidation of the released DA, which results in generation of free radicals in vivo. Enhanced DA autoxidation and oxygen free radicals may initiate a cascade of oxidant stress and lead to injury and loss of SNc neurons in Parkinson's disease. This possibility is supported by increased basal malonaldehyde formation (lipid peroxidation) and iron content in surviving pigmented SN neurons (14) (15) (16) .
For the present work, we studied the implication of DA in the vulnerability of the nigral dopaminergic system to degeneration induced by LPS. We show that the inflammatory degenerative process induced by LPS depends on DA because inhibition of tyrosine hydroxylase (TH) by α-methyl-p-tyrosine (α-MPT) produced considerable protection, as shown by inhibition of the parameters of damage that we studied: dopaminergic degeneration, induction of reactive microglial cells, and loss of astrocytes. Moreover, systemic treatment with L-DOPA/benserazide, which avoids TH inhibition induced by α-MPT, reversed the protective effect produced by α-MPT. The involvement of DA in this process may explain the special susceptibility of the SN dopaminergic neurons to the inflammatory process.
MATERIALS AND METHODS

Animals and surgery
Male albino Wistar rats (weighing 200-250 g) were used for this study. The rats were kept, three or four rats per cage, at a constant room temperature of 22 ± 1°C and relative humidity (60%), with a 12-h light-dark cycle and free access to food and water unless otherwise noted. Rats were anesthetized with chloral hydrate (400 mg/kg) and positioned in a stereotaxic apparatus (Kopf Instruments, Tujunga, CA) to conform to the brain atlas of Paxinos and Watson (17) . Injections into the left SN were made 5.5 mm posterior, 1.8 mm lateral, and 8.3 mm ventral to the bregma.
Experiments were carried out in accordance with the Guidelines of the European Union Council (86/609/EU), following the Spanish regulations (BOE 67/8509-12, 1998) for the use of laboratory animals and approved by the Scientific Committee of the University of Sevilla.
Five groups of animals were established according to the different treatments used: 1) the vehicle-injected group received a single 2-µl intranigral injection of Monastral Blue inert tracer (Sigma-Aldrich, St. Louis, MO; 1% tracer in PBS); 2) the LPS-injected group received a single intranigral injection of LPS (2 µg; from Escherichia coli serotype O26:B6; Sigma-Aldrich) dissolved in 2 µl of vehicle; 3) the α-MPT (Sigma-Aldrich) group received a single intranigral injection of LPS (as described above) and two daily doses of α-MPT (100, 150, or 200 mg/kg of body weight in saline, the first dose being delivered i.p. just before the LPS injection) for 4 days; 4) the α-MPT-33 group received the same treatment as the 200 mg/kg α-MPT group but animals were housed in a hot environment (33°C) to keep their core temperature within normal values; 5) the α-MPT + L-DOPA + benserazide (α-MPT-B/D) group received an i.p. dose of benserazide (Sigma-Aldrich; 10 mg/kg dissolved in saline) 40 min before the LPS injection. At the time of the LPS injection, animals were also injected i.p. with α-MPT (200 mg/kg) + L-DOPA (25 mg/kg; Sigma-Aldrich) dissolved in saline; from this moment onward, animals received two daily doses of α-MPT + L-DOPA 40 min after the injection of benserazide; this treatment was maintained for 4 days. At 1 wk after surgery, animals used for immunohistological evaluation were perfused through the heart while they were under deep anesthesia (induced by chloral hydrate) with 150-200 ml of 4% paraformaldehyde in phosphate buffer, pH 7.4. Brains were removed and cryoprotected serially in sucrose in PBS, pH 7.4, first in 10% sucrose for 24 h and then in 30% sucrose until they sank (2-5 days). Brains were then frozen in isopentane at -15°C. Animals used for in situ hybridization experiments were killed by decapitation 1 wk after surgery. Their brains were removed and frozen in isopentane at -15°C. At least five animals were used for each group. Because animals given the α-MPT-33 treatment showed elevated mortality, only three rats were included in this group. The schedule of the different treatments is summarized in Fig. 1 .
Temperature measurements
Core (rectal) temperature was measured by using a Seikuve SB-80 digital thermometer. Temperature was measured every 2 h after the different treatments for up to 8 h. These five measurements were averaged to give a single value per animal per day (Fig. 2 ).
Immunohistological evaluation: TH, glial fibrillary acidic protein, and OX-6
Thaw-mounted 25-µm coronal sections were cut via cryostat at -15°C and mounted on gelatincoated slides. Primary antibodies were mouse-derived anti-TH (Calbiochem-Novabiochem, San Diego, CA; 1:200), mouse-derived anti-glial fibrillary acidic protein (anti-GFAP; Chemicon International, Temecula, CA; 1:300), and mouse-derived OX-6 (Serotec, Oxford, UK; 1:200). OX-6 is directed against a monomorphic determinant of rat major histocompatibility complex (MHC) class II antigens, expressed by activated microglial cells but not resting cells. Incubations and washes for all antibodies were in Tris-buffered saline (TBS), pH 7.4. All work was done at room temperature. Sections were washed and then treated with 0.3% hydrogen peroxide in methanol for 20 min, washed again, and incubated in a solution containing TBS and 1% horse serum for 60 min in a humidified chamber. Slides were drained and further incubated with the primary antibody in TBS containing 1% horse serum and 0.25% Triton-X-100 for 24 h. Sections were then rinsed three times for 10 min each in TBS and incubated for 2 h with biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA; 1:200) diluted in TBS containing 0.25% Triton-X-100. Sections were then incubated with ExtrAvidin-Peroxidase solution (SigmaAldrich; 1:100). The peroxidase was visualized by means of a standard diaminobenzidinehydrogen peroxide chromogen reaction for 5 min.
Analysis of immunohistochemistry data
For measurement of areas lacking GFAP immunoreactivity, we used AnalySIS imaging software (Soft Imaging System GmbH, Münster, Germany) coupled to a Polaroid DMC camera (Polaroid, Cambridge, MA) attached to a Leika light microscope (Leika Mikroskopie, Wetzlar, Germany). Cells showing OX-6 immunoreactivity were counted by using five fields per section and five sections per animal. In each section, a systematic sampling of the area occupied by the OX-6-positive cells was made from a random starting point with a grid adjusted to count five fields per section. An unbiased counting frame of known area (40 × 25 µm = 1000 µm 2 ) was superimposed on the tissue section image under a 100 × oil immersion objective.
The TH-positive neuronal population was evaluated by counting the number of neurons per section. Five sections were used per animal, located at levels −4.9, −5.2, −5.5, −5.8, and −6.1 mm with respect to the bregma.
Preparation of riboprobes
The rat TH cDNA cloned in PGEM-4Z as a 380-bp EcoRI-KpnI insert was kindly provided by Dr. P. Sokoloff (INSERM, Paris). To prepare the TH antisense riboprobe, this plasmid was linearized with EcoRI and used as a template with the T7 RNA polymerase (18) . To prepare the TH sense riboprobe, the plasmid was linearized with SmaI and was used as a template with the Sp6 RNA polymerase (18) .
The rat dopamine transporter (DAT) cDNA contained in a 800-bp XbaI-HindIII fragment cloned in pRc/CMV (Invitrogen, Carlsbad, CA) was kindly provided by Dr. M. P. Martres (INSERM, Paris). This plasmid was linearized with XbaI and used as a template with the T7 RNA polymerase to prepare the DAT antisense riboprobe. To prepare the DAT sense riboprobe, the same plasmid was linearized with HindIII and used as a template with the Sp6 RNA polymerase (18) . pBluescript SK plasmids, containing the cDNA sequence for the 67-kDa isoform of glutamic acid decarboxylase (GAD67) as a 3.2-kb EcoRI insert (clones 14 and 18), were kindly provided by Dr. A. Tobin (UCLA, Los Angeles, CA). The GAD67 cDNA was isolated from a 1 gt-11 cDNA library made from poly(A) RNA from adult rat brain (19) . To prepare the GAD67 antisense transcript, clone 14 was digested with SalI and used as a template with the T3 RNA polymerase. To prepare the GAD67 sense transcript, clone 18 was digested with SalI and used as a template with the T3 RNA polymerase.
Sense and antisense riboprobes used for in situ hybridization were transcribed in the presence of 35 S-labeled UTP (1300 Ci/mmol; Amersham Biosciences, Piscataway, NJ). Single-strand antisense cRNA probes were synthesized with RNA polymerases according to a protocol provided by the RNA polymerase supplier (Bethesda Research Laboratories, Bethesda, MD).
Isotopic in situ hybridization histochemistry
In situ hybridization with brain frozen sections was carried out by using a modification of a procedure described in detail elsewhere (20) . Thaw-mounted 12-µm coronal sections were postfixed for 30 min in 4% paraformaldehyde, followed by three 10-min washes in PBS (pH 7.4). Sections were treated for 1 min in 0.1 M triethanolamine, followed by 10 min in acetic anhydride/0.1 M triethanolamine to decrease nonspecific binding. After a 1-min wash in 2× standard saline citrate (SSC), sections were dehydrated in a series of increasing concentrations of ethanol and then air-dried. The sections were hybridized for 3 h at 50°C with 35 S-labeled cRNA and rinsed first in 4× SSC/20 mM dithiothreitol and then in 4× SSC alone. Sections were subjected to 30 min of RNase digestion at 37°C (20 µg/ml RNase A in 0.5 M NaCl, 0.01 M TrisHCl, 0.001 M EDTA; pH 8.0), washed for 2 h in 2× SSC at 25°C followed by 0.1× SSC at 60°C for 1 h, dehydrated in a series of ethanol, air-dried, and processed for emulsion autoradiography. Autoradiograms were generated by apposing the labeled tissue to ßmax Hyperfilm (Eastman Kodak, Rochester, NY) for 2 wk. After looking at the dry film autoradiography, slides were dipped in Amersham LT1 emulsion (diluted 1:1 with water) and exposed in the dark for 10-15 days at 4°C. Slides were then developed in D-19 (Eastman Kodak) at 15°C for 2.5 min, fixed for 10 min in fixer (Eastman Kodak), and counterstained with cresyl violet (Sigma-Aldrich).
Analysis of in situ hybridization data
For measurement of expression of TH, DAT, and GAD67 mRNAs in brain sections, we quantified silver grain densities over individual cell bodies by using the image analysis software AnalySIS. Labeling was considered specific when grain accumulation over cells with a large nucleus exceeded five times the background value. The area with high grain density over individual cell bodies was delineated, and the number of grains within this field was counted by means of the computerized image analysis system with a 40 × magnification lens. Because of the high levels of labeling, the typical disposition of the clusters over the cell body, and the high magnification, this delineation was unequivocal. Grains were counted in surviving cells close to the injection site, and only well-separated cells were selected for quantification. Five animals were analyzed for each treatment.
Statistical analysis
Results are typically expressed as means ± SD. Means were compared. Results were analyzed by one-way ANOVA. The least significant difference (LSD) test was used for post-hoc multiplerange comparisons.
RESULTS
Core temperatures of rats given different treatments
To test whether the effects of the different treatments were due to induced hypothermia, we measured core (rectal) temperatures of the animals ( 
α-MPT prevented LPS-induced damage of dopaminergic neurons
Damage to the dopaminergic neuronal phenotype induced by intranigral injection of LPS was prevented by treatment with α-MPT (Fig. 3) . We quantified the effect of the different treatments on the TH-positive neuronal population by counting the number of neurons per section. Injection of 2 µg of LPS into the SN reduced the number of TH-positive cell bodies to 59.3% of the vehicle-injected animals (63 ± 15 cells/section, P<0.01 compared with the vehicle group); this treatment clearly altered the normal pattern of immunostaining of both cell bodies and fibers (Fig. 3A) . α-MPT treatment at doses of 150 and 200 mg/kg led to recovery of the number of neuronal cell bodies (102 ± 22 and 101 ± 9 cells/section, respectively) to levels close to those of vehicle-injected animals (112 ± 23 cells/section). Neuronal cell bodies and fibers were found close to (i.e., around) the injection track (Fig. 3B) . The α-MPT-33 group also showed recovery of the TH-positive neuronal population to control values (109 ± 25 cells/section), which indicated that protection exerted by α-MPT was not due to its hypothermic effect. When inhibition of TH was avoided by treatment with α-MPT + L-DOPA + benserazide, the number of TH-positive neurons resembled that found for the LPS-treated group (68 ± 18 cells/section, P<0.001 compared with the vehicle group), which suggests that DA was involved in LPSinduced damage.
We also measured the expression levels of TH (Fig. 4) and DAT (Fig. 5 ) mRNAs after the different treatments by using in situ hybridization to count silver grains in the surviving neurons around the injection sites. The normal pattern of TH mRNA expression (Fig. 4A, B) was clearly altered by the LPS injection (Fig. 4C, D) ; quantification (Fig. 6A) showed a decrease to 76.6 ± 11.1% (P<0.001) of control values. α-MPT treatment caused recovery of the expression pattern (Fig. 4E, F) , to 121.7 ± 5.2% (P<0.001) of control values. After avoiding (with L-DOPA + benserazide) the TH inhibition produced by the α-MPT treatment, TH mRNA expression decreased again (Fig. 4G, H) to levels close to those observed for LPS treatment (83.2 ± 4.2% of control values, P<0.001). DAT mRNA expression was also altered by LPS (Fig. 5A-D) ; it decreased to 87.6 ± 2.6% (P<0.001) of control values (Fig. 6B) . α-MPT treatment caused recovery of the expression pattern (Fig. 5E, F) to 94.6 ± 0.4 of control values. Treatment with L-DOPA + benserazide again reduced DAT mRNA expression (Fig. 5G, H) to 77.8 ± 5.6% (P<0.001) of control values.
GAD-positive neurons were not affected by these treatments
We previously showed that injection of LPS within the nigrostriatal pathway had no apparent effect on the nigral GABAergic population in terms of GAD67 mRNA-expressing cells/mm 2 (10). We studied the expression level of this marker in the different treatments assayed here (Fig.  7) and again found no significant effect of LPS (alone or in combination with the other agents) on the GABAergic population.
α-MPT prevented LPS-induced activation of microglial cells
We used OX-6 immunostaining to study the effect of α-MPT treatment on microglial activation induced by LPS (Fig. 8 ). OX-6 is directed against a monomorphic determinant of rat MHC class II antigens, expressed by activated microglial cells but not resting cells. We can thus visualize "activated" cells, which are characterized by thicker processes and larger cell bodies than cells in control brains, as well as "phagocytic" microglial cells, with pseudopodic to globular morphology, mostly lacking processes and resembling lipid-laden cells. Injection of 2 µg of LPS into the SN (Fig. 8A ) produced microglial activation that extended to a wide area beyond the injection track and produced a 15-fold increase (Fig. 8G ) in the number of OX-6-positive cells (2983 ± 756 cells/mm 2 ) compared with vehicle-injected animals (194 ± 18 cells/mm 2 , P<0.001). Phagocytic microglial cells were densely packed around the injection track, masked for the tracer. Outside of the track, activated microglial cells were predominant (Fig. 8B) , although some phagocytic cells were also visible. The injection of 2 µl of vehicle into the SN did not induce microglial activation outside the injection track, where some nonspecific mechanical damage appeared (photograph not shown). α-MPT treatment (Fig. 8C) clearly reduced glial activation around the LPS injection site in a dose-dependent manner. Activated and phagocytic microglial cells were mostly restricted to the injection track and masked by the tracer, whereas the section was almost free of activated cells; the density of OX-6-positive microglial cells was reduced to 807 ± 176, 309 ± 23, and 358 ± 109 cells/mm 2 after treatment with 100, 150, and 200 mg/kg α-MPT, respectively (Fig. 8G, P<0 .001 compared with LPS-treated animals). Microglial activation in the α-MPT-33 group (850 ± 314 cells/mm 2 ) was higher than in the other α-MPT groups but still much lower that in the LPS group, which suggests that hypothermia was not responsible for the decrease in microglial activation caused by 200 mg/kg α-MPT. Avoidance of TH inhibition by α-MPT + L-DOPA + benserazide treatment kept the microglial activation value (557 ± 155 cells/mm 2 ) closer to that for the α-MPT group than that for the LPS-injected group.
α-MPT prevented LPS-induced loss of astrocytes
Astroglial cells were stained with an anti-GFAP monoclonal antibody (Fig. 9) . Injection of 2 µl of vehicle into the SN did not alter GFAP immunoreactivity (not shown), which was evenly distributed throughout the section. No lack of staining was found (noted as not detectable in Fig.  9G ). The injection of 2 µg of LPS into the SN produced an area devoid of GFAP immunoreactivity around the injection site (Fig. 9A) . Although astrogliosis is an expected reaction to inflammogens, lack of GFAP immunostaining was previously shown after different insults (10) and was then considered as a marker of damage. α-MPT treatment significantly reduced, in a dose-dependent manner, the loss of GFAP immunostaining (Fig. 9C) around the injection track induced by the LPS-injection (1.38 ± 0.48 mm 2 for LPS; 1.41 ± 0.32, 0.82 ± 0.14, and 0.17 ± 0.07 mm 2 for 100, 150, and 200 mg/kg α-MPT, respectively; see Fig. 9G for statistical comparison). α-MPT treatment also prevented formation of GFAP-immunopositive debris from degenerated hypertrophic astrocytes that were induced by LPS (Fig. 9D) . As observed for the TH-positive neuronal population, GFAP immunostaining loss was also reduced in the α-MPT-33 group (0.42 ± 0.24 mm 2 , P<0.001 compared with the LPS-treated group), which shows that protection exerted by α-MPT was not due to its hypothermic effect. Again, when inhibition of TH was avoided by treatment with L-DOPA + benserazide, loss of GFAP immunostaining (1.21 ± 0.09 mm 2 ) resembled that found in the LPS-treated group, which suggests that DA is involved in LPS-induced damage.
DISCUSSION
To test the involvement of DA in the degeneration induced by LPS, we treated albino Wistar rats with different concentrations (100, 150, and 200 mg/kg of body weight, i.p.) of α-MPT, a wellknown inhibitor of TH activity. We then studied the induction of an inflammatory process along with degeneration of dopaminergic neurons. α-MPT is known to inhibit TH and blocks synthesis of cytoplasmic DA (21, 22) . Pretreatment with α-MPT reduces DA content by 79% (23). Our results show that α-MPT prevented, in a dose-dependent manner, the loss of dopaminergic neurons induced by LPS (measured as the number of TH-positive neurons remaining after LPS challenge, and also as the expression of mRNAs for TH and the DA transporter). In addition, intranigral injection of LPS in the α-MPT-treated animals could not induce an inflammatory process (activation of microglial cells characterized by a change of morphology from resting, ramified cells with thin processes, to reactive microglial cells that eventually become phagocytic) and also the loss of astrocytes accompanied by the appearance of GFAPimmunoreactive debris from hypertrophic, degenerating astrocytes.
Neuroprotective effects of some drugs appear related to their influence on thermoregulation rather than their primary pharmacological effects (24-30). It is known that catecholaminedepleting agents such as α-MPT produce hypothermia, which might provide nonspecific neuroprotection against the effects induced by microinfusion of LPS. However, the protective effects of α-MPT observed in our study seemed to result from the decrease in endogenous DA synthesis caused by inhibition of TH rather than from hypothermia. This assertion is supported by the following findings: 1) the concentration of 150 mg/kg α-MPT did not produce any significant change in the rat's core temperature but had a neuroprotective effect in all parameters assayed. 2) We conducted two different sets of experiments with 200 mg/kg α-MPT: one at room temperature (22°C) and the other at the increased ambient temperature of 33°C in an effort to keep the core temperature of these animals within its normal values. Both groups of animals showed no difference in the results, especially in terms of protection of dopaminergic neurodegeneration. 3) Treatment with L-DOPA and benserazide (an inhibitor of peripheral aromatic acid decarboxylase) is known to increase extracellular levels of DA in the SN approximately fourfold with respect to basal levels (31). This treatment avoided the inhibition of TH produced by α-MPT (200 mg/kg) and restored the degenerative effect induced by LPS on dopaminergic neurons and the loss of astrocytes measured by GFAP immunostaining. All these results strongly support the implication of DA in dopaminergic neurodegeneration induced by LPS in the SN. Moreover, not only did DA seem to be involved in dopaminergic degeneration of the SN but it could also be responsible for the special sensitivity of the SN to inflammation induced by LPS. The SN inflammatory response to LPS injection after TH inhibition was similar to that described for other brain areas, where LPS had little or no effect on neuron degeneration or the glial inflammatory process (10, 11). However, present and previous results (10) have shown that the GABAergic neuronal population in the nigrostriatal pathway is not affected by LPS or by treatments used for altering endogenous DA concentration.
However, treatment with LPS + α-MPT + L-DOPA/benserazide did not produce activation of microglial cells, although it induced damage to astroglia. This result is quite intriguing. Pawate et al. (32) recently pointed out that the glial inflammatory response to LPS and interferon-γ is under redox regulation. They also showed that hydrogen peroxide is the reactive oxygen species (ROS) involved. This finding suggests that in the SN, DA (as one of the main producers of hydrogen peroxide) could have a synergistic effect on proinflammatory compounds as LPS. The main difference between astrocytes and microglial cells as related to the DA pathway could be that dopamine decarboxylase and monoamine oxidase have not been described in microglial cells. This difference could explain why the LPS + α-MPT + L-DOPA/benserazide treatment was unable to induce microglial activation because microglial cells would be unable to both synthesize and catabolize DA with monoamine oxidase. However, it cannot explain why physiologically synthesized DA can interact with LPS to induce microglial activation. This result means that it may be assumed that "physiological" DA, in contrast to that synthesized from L-DOPA/benserazide, may be able to interact with LPS in a special manner to induce microglial activation.
The synergistic effect between DA and other toxins has been described. DA produced a synergistic increase of the toxic action of iron(III) and rotenone (33, 34). Moreover, the toxic action of different compounds has been described to depend on DA. Xu et al. (35) showed that α-synuclein accumulation in cultured human dopaminergic neurons resulting in apoptosis required endogenous DA production and was mediated by ROS. In contrast, α-synuclein is not toxic in nondopaminergic human cortical neurons; rather, it is neuroprotective. Dong et al. (36) showed that recombinant adeno-associated virus-mediated CDCrel-1 gene transfer to the SN of rats resulted in a rapid onset (6-10 days) of nigral and striatal CDCrel-1 expression that was followed by a progressive loss of nigral dopaminergic neurons and a decline in striatal DA levels. In contrast, neurons of the globus pallidus are spared from CDCrel-1 toxicity. Also, DAdependent cytotoxicity of tetrahydrobiopterine (BH 4 ) has been described (37) . BH 4 is an absolute requirement for TH activity and is toxic only to DA-producing cells.
All these results point out the important contribution of endogenous DA to the vulnerability and degeneration of dopaminergic neurons of the SN. They show that the presence of endogenous DA in dopaminergic neurons makes nontoxic compounds (such as α-synuclein, parkin, BH 4 , and LPS) become toxic. In addition, endogenous DA (probably through a synergistic action with inflammatory processes) increases the toxicity and specificity of different toxins. Dong et al. (36) provided a possible reason for this effect in relation to inhibition of DA secretion produced by CDCrel-1. Lotharius and Brundin (38) suggested that α-synuclein produced inhibition of phospholipase D2, which led to incomplete DA vesicle recycling with the consequent increase in free DA and free radicals. LPS is known to induce free radicals. LPS-stimulated release of superoxide is mediated by NADPH oxidase, which is the primary superoxide-producing enzyme in phagocytic cells of the peripheral system and brain (39) . Moreover, LPS produces selective up-regulation of the inducible nitric oxide synthase, with production of nitric oxide (40) , which can react with superoxide to form the powerful oxidant peroxynitrite. The combination of the intrinsic characteristics of dopaminergic neurons and their reduced ability to detoxify ROS renders dopaminergic neurons more sensitive to attacks by free radicals generated both extracellularly and intracellularly. Endogenous DA and LPS could act in synergy to induce release of free radicals, with a consequent increase in toxicity and specificity of different toxins to dopaminergic neurons.
Our results support the involvement of endogenous DA in the special susceptibility of dopaminergic neurons to insults that may be responsible for development of PD (41) . Knowledge about the way in which DA is involved in this process may lead to the possibility of new protection strategies against this important degenerative process. A) GFAP immunoreactivity in an LPS-injected animal. The arrow points to the site of injection of 2 µg of LPS. The tracer is clearly visible within the area lacking GFAP immunostaining. GFAP expression was more intense around the area lacking immunoreactivity. B) High-magnification image corresponding to the outlined area in A. The damaged area contained GFAP-positive debris from degenerated hypertrophic astrocytes (arrows). C) GFAP immunoreactivity in an animal treated with α-MPT (150 mg/kg) + LPS. The arrow points to the injection site. The area lacking GFAP immunostaining was clearly reduced compared with that in A. D) High-magnification image corresponding to the outlined area in C. Some hypertrophic (arrow) and normal (arrowhead) GFAP-positive structures were found. E) GFAP immunoreactivity in an animal treated with α-MPT-B/D + LPS. The arrow points to the site of injection of 2 µg of LPS. The area devoid of staining was similar to that observed in LPS-treated animals. F) High-magnification image corresponding to the outlined area in E. Some GFAP-positive hypertrophic profiles were found. Scale bars for A, C, and E = 500 µm; scale bars for B, D, and F = 50 µm. G) Quantification of areas lacking GFAP immunoreactivity in the SN of rats after the treatments indicated in Fig. 1 . Results are means ± SD of five independent experiments and are expressed in mm 2 . One-way ANOVA followed by the LSD post-hoc test for multiple comparisons was used for statistical analysis, with α = 0.05: a, significantly different compared with LPS-injected animals; P < 0.001. N.D., not detectable, meaning that injection of vehicle produced no lack of GFAP immunostaining.
